REG - MyHealthChecked PLC - Partnership with Lloyds for COVID Antigen testing

MyhealthcheckedAnnouncement

05/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220105:nRSE4278Xa&default-theme=true

RNS Number : 4278X  MyHealthChecked PLC  05 January 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

MyHealthChecked Plc

("MyHealthChecked", "MHC" or the "Company")

 

Retail partnership with Lloyds Pharmacy for COVID-19 Antigen testing

 

MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company,
has signed a contract with AAH Pharmaceuticals Limited ("Lloyds Pharmacy") for
supply of the Fit to Fly/Pre-departure rapid antigen test. The test can be
taken at home prior to travel, or overseas prior to returning to the UK, with
results verified by a trained professional within two hours of completing the
test, and provides the passenger with a certificate suitable for outbound or
return travel.

 

The rapid antigen tests and accompanying verification service provided by
MyHealthChecked will be the only COVID rapid antigen test sold through Lloyds
Pharmacy and will accompany the portfolio of PCR kits that the pharmacy began
selling online in August.

 

The Fit to Fly rapid tests will launch at Lloyds Pharmacy in January 2022.

 

Penny McCormick, Chief Executive Officer of MyHealthChecked Plc, said:

"I am pleased to build on our existing relationship with Lloyds Pharmacy with
our new COVID-19 antigen test service for travel. Lloyds Pharmacy is already
well established with a PCR testing portfolio that includes inbound PCR
testing for fully vaccinated and non-vaccinated customers. We are delighted to
be supporting Lloyds Pharmacy further with their growing COVID testing
portfolio and working with them as testing protocols for travel continue to
evolve."

 

 MyHealthChecked plc                                                www.myhealthchecked.com (http://www.myhealthchecked.com)
 Penny McCormick, Chief Executive Officer                           via Walbrook PR
 Gareth Davies, Chief Financial and Operations Officer

 SPARK Advisory Partners Limited (NOMAD)                            Tel: +44 (0)20 3368 3550
 Neil Baldwin

 Oberon Capital Ltd (Broker)                                        Tel: +44 (0)203 179 5344
 Mike Seabrook                                                      mikeseabrook@oberoninvestments.com (mailto:mikeseabrook@oberoninvestments.com)

 Walbrook PR Ltd (Media & IR)      Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
                                   (mailto:myhealthcheckedplc@walbrookpr.com)
 Paul McManus / Alice Woodings                                      Mob: +44(0)7980 541 893 / +44 (0)7407 804 654

 

 

About MyHealthChecked PLC (www.myhealthcheckedplc.com
(http://www.myhealthcheckedplc.com) )

 

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK
healthcare company focused on a range of at-home healthcare and wellness
tests. MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA
tests, now in development following the acquisition of The Genome Store in
November 2020. The tests will be made available online, and would be viable
for over the counter purchase.

 

The MyHealthChecked portfolio has been identified as part of a change in
mindset as customers become more familiar with the concept of accessible
healthcare in the growing at home testing kit market with a focus on
accessibility at the right price, led by UK-based experts.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPUUAGUPPGMC